Remarkably, the Canakinumab Antiinflammatory Thrombosis Outcome Study trial furnishes definitive evidence that inhibition of interleukin (IL)-1β with its monoclonal antibody canakinumab robustly reduced cardiovascular events for patients with atherosclerotic cardiovascular disease (ASCVD) [2], allowing the targeting inflammation to clinical realty. The gene discussed is IL1B; the disease is atherosclerosis.